A new study led by investigators from Mass General Brigham found routine liver cancer screening to be cost-effective and life ...
A new study led by investigators from Mass General Brigham found routine liver cancer screening to be cost-effective and life ...
A bivalent FGF21 analogue, efruxifermin, is linked to an improved fibrosis response in patients with metabolic ...
Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...
Nonalcoholic fatty liver disease (NAFLD), now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe form, nonalcoholic steatohepatitis (NASH), renamed ...
Ramat Gan, Israel, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...
Please provide your email address to receive an email when new articles are posted on . Patients with PBC and cirrhosis treated with seladelpar exhibited greater reductions in ALP, GGT and ALT at 12 ...
A case report and literature review describes a cirrhotic patient with L1/2 spondylitis caused by both Lactococcus lactis and ...
Cirrhosis can also develop in a transplanted liver, and most often this is due to the return of the disease that caused the patient to need a transplant. In a study involving 937 people, repeated ...
A multicenter Chinese study of 851 patients found that the neutrophil-to-lymphocyte ratio independently predicts in-hospital ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results